Interview: Joan Josep Berbel, Director, Invest in Catalonia
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
The Indukern Group is a group of Spanish multinational companies founded in 1952 based in Madrid. Its main activities are focused on the pharmaceutical, chemical, food and veterinary industries, among others through its three business areas; Indukern, Calier, and Kern Pharma.
With five business divisions, Indukern is a leading specialist firm in chemicals distribution and value-added activities of formulation, production, and technical advice for various industry sectors.
Calier is a research, development and marketing company of pharmacological and biological products for livestock and pets.
Kern Pharma works in the development, manufacture and marketing of pharmaceutical products, with emphasis on generics and ethicals. It also markets products for the OTC market, biosimilars, women’s health, health and sports nutrition, and production for other companies.
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
Walther von Plettenberg, general manager of the German-Spanish Chamber of Commerce in Spain, traces the history of the organization’s activity and highlights the efforts of the Chamber in response to…
Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant…
Emilio Lora-Tamayo, president of the Spanish National Research Council (CSIC), outlines Spain’s current strengths and weaknesses in the areas of research and innovation. Could you please introduce yourself to our…
Despite a number of setbacks in public funding as a result of Spain’s recession, the Spanish National Biotechnology Center (CNB) has continued to remain at the forefront of science and…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and…
The history of AmCham Spain dates back to 1917 and has a critical part of developing bilateral relations between Spain and the United States. The company’s president, Jaime Malet, discusses…
Baxter Spain’s general manager, Luigi Antoniazzi, discusses the challenges that the affiliate has faced in light of recent changes in the market, and the strategies taken to adapt to an…
Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous…
Bernardo de Rafael Topfer, Iberia Country Manager, speaks about how middle-sized companies like Orion can use niche indications to their advantage in the face of strong competition from big pharma’s…
See our Cookie Privacy Policy Here
